Dear our shareholders and Investors,
We express our deepest gratitude for your steadfast support and trust since our establishment in 2008. Our dedication to innovative drug discovery, with a focus on ion channels, has established us as a frontrunner among Japanese biotechnology ventures. Leveraging our comprehensive research infrastructure, we have successfully secured multiple licensing agreements and made significant strides in clinical development.
In the ever-evolving pharmaceutical and biotech landscape, resting on our laurels is not an option. Our unwavering commitment to continuous innovation in technology and therapeutic targets remains strong. Between 2021 and 2023, we have significantly bolstered our efforts both within and beyond our organization. Internally, we have enhanced our drug discovery value chain through the strengthening of our facilities and the development of our human resources. Externally, we have cultivated partnerships and collaborative research endeavors with startups and drug discovery companies globally, achieving notable successes in various projects.
As we launch our new medium-term business plan in 2024, our objective is to amplify these initiatives. We aim to secure substantial contracts through our in-house development, focusing on maximizing corporate value by leading in R&D, staying ahead of competition, and innovating in drug development, while carefully balancing financial and R&D risks.
Looking ahead, our long-term aspiration is to cater to the diverse investment preferences of our shareholders and investors. This strategy encompasses initiatives like share buybacks and dividends, supported by a substantial increase in operating income.
We will continue to provide updates on our specific initiatives through our mid-term management plan, timely disclosures, and online briefings.
Your support and trust are fundamental to our success, and we remain dedicated to meeting these challenges head-on. We sincerely appreciate your ongoing understanding and support of our Group.
President&CEO Hirobumi Takeuchi